- Home
- HLP vs IOBT Comparison
HLP vs IOBT Comparison
Compare HLP & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- IOBT
- Stock Information
- Founded
- HLP 2021
- IOBT 2014
- Country
- HLP China
- IOBT Denmark
- Employees
- HLP N/A
- IOBT N/A
- Industry
- HLP Industrial Machinery/Components
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- IOBT Health Care
- Exchange
- HLP Nasdaq
- IOBT Nasdaq
- Market Cap
- HLP 68.8M
- IOBT 62.6M
- IPO Year
- HLP 2023
- IOBT 2021
- Fundamental
- Price
- HLP $1.66
- IOBT $1.00
- Analyst Decision
- HLP
- IOBT Strong Buy
- Analyst Count
- HLP 0
- IOBT 3
- Target Price
- HLP N/A
- IOBT $9.33
- AVG Volume (30 Days)
- HLP 225.1K
- IOBT 83.8K
- Earning Date
- HLP 06-19-2025
- IOBT 05-20-2025
- Dividend Yield
- HLP N/A
- IOBT N/A
- EPS Growth
- HLP N/A
- IOBT N/A
- EPS
- HLP N/A
- IOBT N/A
- Revenue
- HLP $14,045,084.00
- IOBT N/A
- Revenue This Year
- HLP N/A
- IOBT N/A
- Revenue Next Year
- HLP N/A
- IOBT N/A
- P/E Ratio
- HLP N/A
- IOBT N/A
- Revenue Growth
- HLP N/A
- IOBT N/A
- 52 Week Low
- HLP $0.84
- IOBT $0.66
- 52 Week High
- HLP $2.25
- IOBT $1.79
- Technical
- Relative Strength Index (RSI)
- HLP 76.52
- IOBT 52.54
- Support Level
- HLP $0.92
- IOBT $0.95
- Resistance Level
- HLP $1.06
- IOBT $1.20
- Average True Range (ATR)
- HLP 0.16
- IOBT 0.09
- MACD
- HLP 0.07
- IOBT 0.01
- Stochastic Oscillator
- HLP 100.00
- IOBT 43.10
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.